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Abstract
Infectious diseases threatened humankind countless times through history, 
when knowledge on microorganisms was absent and medical capabilities were 
limited. Pandemics and outbreaks caused death of millions, brought empires to 
their knees and even wiped some ancient civilizations. In “modern” days, despite 
of improved medical application, sanitary precautions and effective medicines, 
infectious diseases are still cause of more than 54% of total mortality in developing 
countries. Millions of people are protected from the infectious diseases annually as 
a result of mass immunization campaigns. Nevertheless, novel diseases as COVID-
19, MERS-CoV, avian influenza, Ebola, Zika and possible future infections require 
dynamic vaccine research and investment. Along with all the advantages of vac-
cines, there are several limitations regarding cost, biosafety/biosecurity, storage, 
distribution, degradation topics. Plant-based vaccine production for humans and 
animals has been under serious consideration to overcome some of these limita-
tions. Nowadays, plant biotechnology brought new insight to vaccines research 
through gene transfer strategies to plants and improvements in amount, isolation 
and purification and addition of adjuvant for production of recombinant vaccine 
antigens in plants. Recombinant vaccines can undeniably offer us new standards 
and legal regulations to be introduced for the development, approval, authoriza-
tion, licensing, distribution and marketing of such vaccines. The aim of this chapter 
is to exploit uses, methods and advantages of recombinant DNA technology and 
novel plant biotechnology applications for plant-based vaccine research in respect 
to existing infectious diseases.
Keywords: Plant-based vaccine, recombinant protein, virus-like particles,  
transgenic plant, molecular farming, oral vaccine, chloroplast transformation, 
transient expression, stable nuclear transformation, COVID-19
1. Introduction
There are many breakthrough events during ongoing human civilization pro-
cess. All of these individual events contributed the process in different significance. 
Nevertheless, agricultural development and animal domestication significantly 
accelerated all the other developments due to the fact that they saved people from 
daily boundary of finding nutrition and allowed more spare time for socialization 
and thinking.
Advantages of settled life style increased population in early cities rapidly. 
Ancient cities as Rome, Athens, Fayum varied in population between a hun-
dred thousand to a million in various eras [1, 2]. Lacking the knowledge of 
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microorganisms, hygiene and sanitation precautions, underdeveloped sewer 
systems and living so close to domesticated animals and people resulted to the 
rise of “civilization pathogens”. It is hypothesized that virulent pathogens were 
present but not persistent due to the limited population in human communities 
before agricultural development and urbanization. Most of the animals tend to live 
together in herds. Even though the herd lifestyle is very suitable for the transmission 
of pathogens, there were limited contact between humans and animals since hunt-
ing was the only viable way. Developments in agriculture and animal domestication 
lifted that barrier and allowed animal diseases to be transmitted to humans more 
frequently in higher population densities. Major fatal human diseases as measles, 
tuberculosis, smallpox, influenza, pertussis, and falciparum malaria are linked to 
early domesticated animals via phylogenetic analysis [3]. Throughout the history of 
human civilization there are several outbreaks of pandemic diseases which shaped 
the world socially, economically and politically (Table 1).
In present day, vaccines are the vital part of the preventive healthcare globally. 
Many of the once deadly diseases are not present for decades, since the mass vac-
cination campaigns were applied worldwide. Based on their production method and 
protection mechanisms, vaccines are categorized under several classes including 
Common Name Year(s) Cause Estimated 
Death (Million)
Plague of Athens 430 B.C. Salmonella enterica 0.1





541–542 Yersinia pestis 30–50
Black Death 1347–1352 Yersinia pestis 75–200
New World 
Smallpox
1520 - NA Variola major and Variola minor 25–55
Italian Plague 1629–1631 Yersinia pestis 1
Great Plague of 
London
1665 Yersinia pestis 0.075–0.1
Third Plague 1885 Yersinia pestis 12
Russian Flu 1889–1890 A/H3N8, A/H2N2, or coronavirus OC43 
(uncertain)
1
Yellow Fewer Late 1800s RNA virus from Flavivirus genus 0.15
Spanish Flu 1918–1920 Influenza strains of A/H1N1 50
Asian Flu 1957–1958 Influenza A virus subtype H2N2 1
Hong Kong Flu 1968–1970 H3N2 strain of the influenza A virus 1
HIV-AIDS 1981-ongoing Lentivirus 35 and counting
SARS 2002–2003 Coronavirus (SARS-CoV-1) <0.001
Swine Flu 2009 H1N1 influenza virus 0.2
MERS 2015 Coronavirus (MERS-CoV) <0.001
Ebola 2014–2016 Ebolaviruses 0.011
Covid-19 2019-ongoing Coronavirus (SARS-CoV-2) 2.52 and 
counting
Table 1. 
Major outbreak throughout the history of human civilizations [4].
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live attenuated, inactive (killed whole organism), toxoid, subunit (purified native 
or recombinant protein, polysaccharide or peptide), virus-like particle, outer 
membrane particle, protein-polysaccharide conjugate, viral vectored, nucleic acid, 
bacterial vectored, antigen-presenting cell vaccines [5, 6]. Despite the various new 
approaches to the vaccine production, most of the vaccines which are applied in 
immunization programs are either live attenuated, inactive or subunit vaccines. 
WHO (World Health Organization) vaccine-preventable diseases: monitoring sys-
tem [7] offers important and comparable data on this topic based on all countries. 
Even so, there are public concerns over the topics as age and schedule of vaccina-
tion, common (injection site pain, redness and swelling, fever, malaise, headache) 
and rare side effects (anaphylaxis, idiopathic thrombocytopenic purpura, nar-
colepsy, autism), immunodeficiency or antigenic overload issues. As in all daily 
life matters, misinformation on these topics and issues in social media and search 
engines greatly challenges vaccine production methods and public acceptance, 
although the scientific evidences prove the contrary.
As illustrated in Figure 1, one of the greatest challenges in vaccine research is 
based on logistics and distribution. Along with post-production purification and 
packaging issues, logistics of traditional vaccines under cold chain conditions in 
limiting shelf-life durations exhibit certain difficulties [6]. Especially in underde-
veloped countries, lack of health infrastructure and required conditions threaten 
overall process. Moreover, world once again faced the same dilemma in Covid-19 
pandemic as 16 of total 256 vaccine candidates passed to phase III trials by February, 
2021 [8]. These manufacturers announced their plans to produce 10 billion doses (at 
least 2 doses are required for immunity in most) until the end of 2021 in their best 
estimations. Apparent insufficient annual production capacity leads priority groups 
to be formed for the early products. As in this latest ongoing example, inequity in 
access to vaccines is always a major issue [9].
Leading Covid-19 vaccine candidates are mainly developed by private/industry 
association by 72%. Remaining 28% is consisted of academic, public and non-profit 
organizations. Also, there are bigger multinational vast vaccine manufacturer 
companies as Janssen, Sanofi, Pfizer and GlaxoSmithKline which may ensure 
tolerating lack of large scale vaccine manufacturing inexperience and capacities 
of these relatively smaller organizations [10]. Even though, commercial viability 
Figure 1. 
Main global challenges in vaccine research.
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apparently is not an issue for potential Covid-19 vaccine, it is a real drawback for 
many diseases. These diseases are mostly have devastating effects on restricted 
local areas as poor communities. In case of such rare infection diseases, develop-
ment costs offset potential income. Vaccines against this kind of diseases as Ebola, 
which multinational manufacturers hesitate to invest due to commercial viability, 
are called ‘orphan vaccines’ [11]. More profitable vaccine production methods may 
withdraw hesitation over these diseases which are only producible with government 
assistance and still have high mortality rates regionally.
Another and probably the most challenging factor in vaccine research is based 
on immunological issues. Commercially viable vaccine targets for diseases like HIV, 
gonorrhea (Neisseria gonorrhoeae), syphilis (Treponema pallidum), malaria or sea-
sonal influenza are generally caused by highly variable pathogens. These pathogens 
present variation both in and between host variations which emerge difficulty to 
identify common antigen target for immunization by vaccine. Some people produce 
natural antibodies against more conserved antigens of pathogens and have enhanced 
immunity but targeting these conserved antigens by vaccine induction has not been 
achieved for many of these diseases yet. Protection efficacy is a major issue due to the 
immunological variations even in post-production of the vaccines [6]. Even so, global 
reports over novel mutations of the virus will require re-evaluation of efficacy values 
and raise suspicion in public for existing vaccines. In some case as RTSS vaccine which 
is licensed for malaria disease, efficacy is lower as 30–40%. Therefore, considering 
all immunological factors together suggests long development time of traditional 
vaccines fail to satisfy rapid, flexible and upscale production requirements [6].
Following the rapid development of biotechnology and bioinformatics, precise 
genomic and proteomic target identification methods and instruments are emerged. 
Therefore, knowledge on structural biology and immunology is mostly available for 
many infectious diseases. Deciding vaccine production methods is based on deliv-
ery, immunogenicity, production capacity and speed, transport requirements and 
shelf life and economic viability. Along with the methods as viral vectored vaccines, 
nucleic acid-based vaccines, RNA vaccines, outer membrane vesicles, plant based 
vaccines present promising contribution to the field. Experimental and commercial 
applications of plant based vaccines will be evaluated further in this chapter in 
perspective of future preventive healthcare alternative.
2. Plant-based vaccine production
Especially in the last two decades, the expression studies of vaccine antigens in 
plants have been accelerated with the developments in the production of recom-
binant proteins in plants and it has been provided possibility to design effective 
plant-based vaccines against many diseases. In this process, both developments in 
transgenic approaches and transformation methods and improvements in various 
areas such as promoter selection, codon optimization, plastid transformation for 
increasing yield of recombinant protein have paved the way for the production of 
vaccine antigens. The significant increase in the world population and the emer-
gence of epidemic and pandemic diseases cause demands that exceed the vaccine 
production capacity. However, the success of national vaccine programs is marred 
by both high cost-per-dose of producing vaccines and the limitations in the distri-
bution of vaccine. In addition, there is a risk of exposure to dangerous pathogens 
caused by injection procedures during vaccination, resulting in diseases like HIV, 
hepatite C that can be transmitted through blood. Moreover, risk of contamination 
of other viruses such as SV40 and foamy virus, which can cause disease in humans 
and animals, is another important factor that should be evaluated in terms of 
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health, although it depends on the nature of the vaccine (attenuated or inactivated), 
the titer of the contaminant, the degree of inactivation and pathogenicity [12]. 
When all these disadvantages are examined, it is seen that the use of plant systems 
for vaccine production has the potential to provide a biotechnological solution, 
considering that it can provide high-scale production and reduce the cost-per-dose 
and minimize the problems that may occur during vaccine production and distribu-
tion. While plants produce complex proteins similar to other eukaryotic systems, 
they can fold and modify these proteins post-translationally. However, they contain 
minor differences in glucosylation patterns compared to mammalian cells [13].
In general, the technical points taken into consideration for the plant transfor-
mation and the production of recombinant protein in plants should also be taken 
into account in planning for the production of recombinant vaccine antigens in 
plant systems. Two different systems are used in the production of recombinant 
proteins in plants known as stable genetic transformation and transient gene 
expression. Stable nuclear transformation results in stable expression in plant tis-
sues by ensuring the insertion of recombinant DNA into the nuclear genome of the 
plant cell [13]. In addition, transgenes can stably integrate into the plastid genome 
other than the nuclear genome. The transfer of recombinant DNA is carried out by 
using direct and indirect methods and this preference varies according to the target 
plant species, target genome (nuclear or plastid), gene construct to be introduced. 
Natural plant pathogens, Agrobacterium tumefaciens and Agrobacterium rhizogenes 
are used for indirect gene transfer and are generally preferred for nuclear trans-
formation. Biolistic or microparticle bombardment, which is the most preferred 
among direct methods, are mostly used in the transformation of the plastid genome 
and plant species where transformation mediated by Agrobacterium species is not 
applicable. By using plant tissue culture methods with all these transformation 
methods, a whole transgenic plant can be obtained or plant tissue cultures (callus, 
hairy root) can be established for recombinant protein production from various 
plant tissues. In addition, by using plant tissues for recombinant protein produc-
tion, plant cell cultures also become prominent as an alternative system. Generally, 
transgenic plants allow large-scale production of recombinant proteins with high 
expression of introduced gene. This system can also enable the production of 
multiple recombinant proteins in a single plant by crossing different transgenic 
plants. On the other hand, development of transgenic plants by stable transforma-
tion is relatively more time consuming and also needs improvement due to the 
low protein expression compared to other plant systems. Another disadvantage is 
that the transgene may show different profiles in its expression due to positional 
effect as a result of random entry into the nuclear genome. Moreover, in case of 
multiple insertions, unstable gene expression and gene silencing may occur. On the 
other hand, transient expression has many advantages for the expression of genes 
encoding recombinant proteins in plant tissues. Two processes are particularly 
prominent for transient transformation in plants named as transient expression of 
the transgene by Agrobacterium infiltration and viral vector-based transient expres-
sion. These two processes are based on the expression of transgenes transported by 
bacteria or virus vectors, and stable integration of the transgene into the genome is 
not required. The most important advantage of these systems is rapid recombinant 
protein production. Expression of extra chromosomal transgenes can be detected 
in 3–4 hours after DNA transfer, while it can reach the maximum expression level 
in 18–48 hours [14]. Gene expression can be maintained for 10–14 days, afterwards. 
Transient based expression is generally at a higher level than stable transformation. 
Plant viral vectors used for viral vector-based transient expression, can be preferred 
to increase the number of gene copies that can result in a much higher protein yield 
compared to stable transformation. Various RNA viruses such as tobacco mosaic 
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virus (TMV), cauliflower mosaic virus (CMV), alfalfa mosaic virus (AVM) are used 
to construct plant viral expression vectors.
2.1 Nuclear transformation
It is ensured that vaccine antigens can be produced in large amounts in the tis-
sues of transgenic plants that are transformed by nuclear transformation, and oral 
administration of the vaccine becomes possible thanks to the expression in edible plant 
organs in such as lettuce (Lactuca sativa). The gene integrated into nuclear genome 
can be maintained with transgenic seeds and replanted when needed. Moreover, by 
crossing different transgenic plants, different transgenes can be included in a single 
plant, allowing development of different characteristics of the plant in a short time. 
Transgenic plant lines, depending on the plant species, can be developed in a shorter 
time by nuclear transformation than chloroplast transformation. Recombinant vaccine 
antigens produced by nuclear transformation can be targeted to a variety of organelles 
such as chloroplasts, vacuoles and endoplasmic reticulum owing to signal peptides, 
and various post-translational modifications can be achieved particularly in the endo-
plasmic reticulum. On the other hand, the disadvantage of nuclear transformation is 
that it displays relatively low levels of expression compared to chloroplast transforma-
tion and transient expression, as well as position effect and gene silencing [15].
For many years, the nuclear genome has been the main target of plant gene 
transfer studies, which has enabled the production of recombinant vaccine antigens 
by nuclear transformation in plants to come to the fore and to be performed rela-
tively easily. Thanks to nuclear transformation in plants, the production of vaccines 
against many disease factors from enteric bacteria to viruses that threaten human 
and animal health has been achieved (Table 2).
Every day, 200 million people in the world experience health problems due to 
gastroenteritis. In developing countries, more than 2 million people die annually 
from such enteric diseases [23]. It has been reported that a multiepitopic protein 
from the antigens of enterotoxigenic E. coli, S. typhimurium and V. parahaemolyticus 
bacteria for use against these diseases is expressed in fresh leaf tissue as much 
as 5.29 μg g−1 in tobacco (Nicotiana tabacum) plants by A. tumefaciens-mediated 
transformation. Plant-made LTBentero antigen was found to be immunogenic 
when administered orally or subcutaneously to BALB/c mice, this antigen was 
also able to induce specific IgG (systemic) and IgA (mucosal) responses against 
LTB, ST, and LptD epitopes [23]. Moreover, by regulating the quality processes of 
transgenic plant-based vaccines, it has been ensured that the quality differences in 
the production steps are minimized. Especially for this purpose, closed hydroponic 
plant growing systems were established and oral cholera vaccine (MucoRice-CTB) 
was produced in accordance with legal regulations within the scope of “Good 
Manufacturing Practices” without the need for purification [24]. Thus, a plant-
based vaccine production system, which can be harvested three times a year and 
is effective in terms of cost and production, has been implemented. Moreover, 
Needle- and cold chain free rice-based oral vaccine MucoRice-CTB has been 
reported to show immunogenicity in humans due to microbiota [25].
In recent years, except advanced monocot and dicot transgenic plants, vari-
ous moss groups in the plant kingdom have started to be preferred for vaccine 
production. Env-based HIV (Human Immunodeficiency Virus) multi-epitope 
protein (poly-HIV) produced in transgenic moss lines has been reported to elicit an 
immune response in mice as a candidate for subunit vaccine. Moss can be propa-
gated under in vitro conditions in accordance with “Good Manufacturing Practices” 
standards and algae biomass does not have an apparent toxic effect. Therefore, this 
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FW: Fresh Weight, Tsb: Total Soluble Protein, NA: Not Available, FTW: Fresh Tuber Weight, CaMV: Cauliflower Mosaic Virus, AIDS: Acquired Immune Deficiency Syndrome. ST: Solanum tuberosum,  
LE: Lycopersicon esculentum.
Table 2. 
Plant-based vaccines developed by nuclear transformation/stable expression system.
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like Physcomitrella patens is able to perform post-translational modifications like 
N-glucosylation identical to higher plants [17].
Considerable efforts have been made to develop methods that can simplify 
the purification procedure as the downstream processing of recombinant vaccine 
antigens will significantly increase production costs. ELPylation as one of these 
methods, generally increases the accumulation of transgenic proteins in plants as 
reported in various examples [18]. In addition, ELPylated proteins can be rapidly 
purified by membrane-based inverse transition cycling (mITC) procedure. Using 
ELPylation, in which an elastin-like polypeptide (ELP) consisting of a series of pen-
tapeptides is fused to the end of the target protein, an increase in antigen accumula-
tion is observed in both transiently and stably transformed plants [26]. It has also 
been reported that the immune response increases significantly with the proper 
folding and trimerization of the antigen. In the study, in which the hemagglutinin 
of the avian influenza virus (AIV HA) was produced as a monomer and ELPylated 
trimer form in the tobacco plant (transient in Nicotiana benthamiana and stable in 
Nicotiana tabacum), it was observed that the trimeric AIV HA form increased the 
specific immune response to HA compared to the monomeric form [26].
Virus-like particles that do not contain viral nucleic acids and are formed by viral 
capsid proteins become prominent as much more reliable candidates when compared 
with attenuated viral vaccines. Studies in which capsid proteins are expressed in 
plants by nuclear transformation have been shown to induce specific antibodies com-
parable to attenuated vaccines when administered orally with an adjuvant [27]. VP2, 
VP6 and VP7 capsid proteins of group A rotavirus, one of the most common cause 
of human pathogen, acute infantile and pediatric gastroenteritis worldwide, have 
been expressed in transgenic tobacco plants. It has been reported to be significantly 
higher IgG antibodies in the serum of mice of the group VP 2/6/7 (immunized with 
transgenic tobacco plants) than group VP 2/6 (immunized with transgenic tobacco 
plants) and the group RV (immunized with orally attenuated RV vaccine) group IgG 
antibodies are significant. In addition, it was reported that the serum IgG titer in the 
VP 2/6 group was almost as high as that found in the RV group [27].
Using the nuclear transformation system, plant-based vaccines can be developed 
on the basis of low-cost multiepitopic recombinant proteins to contain epitope vari-
ants that can induce broad-spectrum antibodies. In addition, sequences contain-
ing adjuvant activity can be added to these multiepitopic proteins. Multiepitopic 
vaccines produced in plants trigger local and systemic immune responses more 
than their counterparts produced in bacteria. In orally inoculated BALBc mice, 
lettuce-derived HIV C4 (V3) 6 multiepitopic protein showed a higher immunogenic 
potential than E. coli-derived HIV C4 (V3) 6 multiepitopic protein [28].
Plant systems are also used in the production of vaccines against various para-
sitic diseases other than bacteria and viruses. Taenia solium cysticercosis is one of 
the important parasitic diseases affecting human health especially in developing 
countries. Production of a low-cost and multi-epitope vaccine against this disease 
was achieved in the tobacco (Nicotiana tabacum) plants by Agrobacterium-mediated 
transformation. The developed transgenic lines were self-pollinated and T1 genera-
tion transgenic plants were obtained from the harvested seeds. In these plants, 
several vaccine-related antigens were expressed in a polyprotein system based 
on the ribosomal skip mechanism via the 2A sequence derived from the foot-and 
mouth virus, which induces self-cleavage events at the translational level [29].
2.2 Chloroplast transformation
This section emphasized on recent advances in creation and development of 
transplastomic plants to produce plant-derived vaccines and protection against 
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infectious diseases. Plastid transformation has come to be advantageous for the pro-
duction of vaccines due to the high copy number in a single transformation allowing 
high levels of transgene expression and the absence of effects leading to gene silenc-
ing and the lack of concerns about positional and pleiotropic effects. In addition, as 
a result of maternal inheritance, the containment of foreign genes in the chloroplast 
genome and the absence of transgenes in the pollen are other advantages. Moreover, 
chloroplast transformation ensures expression of multiple genes in prokaryotic-
like operon systems. However, this system is limited by the insufficient number 
of the target plant variety and the trials of very few plant varieties according to 
nuclear transformation. Another disadvantage is the lack of glucosylation ability of 
chloroplasts. Therefore, difficulty of expression of eukaryotic human or viral genes 
in prokaryotic chloroplasts is most important barrier to the use of transplastomic 
plants. Some major costs associated with the production of recombinant proteins 
in fermentation-based systems can be reduced by using chloroplasts as bioreactors. 
Chloroplast-derived therapeutics, especially when administered orally, eliminate 
expensive purification steps, cold storage, transportation and sterile injection 
requirements [30].
Advances in transgenic approaches and the development of gene gun and biolistic 
(particle bombardment method) technologies have enabled the transgene to be trans-
ferred directly to living cells. With these systems where tungsten and gold particles 
are used as microcarriers, the transformation of plastids can be carried out effectively. 
As an alternative to this system, plastids are transformed via polyethylene glycol 
(PEG) [31, 32]. PEG-mediated transformation allows the simultaneous transforma-
tion of many samples as a simple and efficient method and enables a large number of 
transformed cells with a high survival rate. However, it has a lower success rate than 
biolistic-mediated transformation. Despite its high transformation efficiency, biolistic 
is not available in many laboratories and standardization of its protocol is very dif-
ficult. It has been shown repeatedly that recombinant proteins capable of eliciting 
protective mammalian immune responses can also be produced in chloroplasts of 
plants. Thanks to chloroplast transformation, vaccines can be produced against viral 
diseases such as polio (poliovirus), human immunodeficiency (HIV), human papil-
loma virus (HPV), as well as numerous contagious and fatal bacterial infections and 
diseases such as cholera, tuberculosis, plague and anthrax (Table 3).
Virus-like particles formed by viral capsid proteins that do not contain viral 
nucleic acids are frequently preferred within vaccine production in plants due 
to their ability to elicit protective immune responses. In this context, Lenzi et al. 
[56] reported that the self-assembled L1 capsid protein of human papilloma virus 
(HPV), that is the causative agent of cervical cancer which is one of the most com-
mon causes of death for women, can be produced in chloroplasts of the Nicotiana 
tabacum plant. Thus, in tobacco chloroplasts, the HPV-16 L1 vaccine could be 
produced by expression of the L1 protein from a natural viral (L1v gene) or a syn-
thetic sequence (L1pt gene) optimized for expression, under the control of plastid 
expression signals. In addition, accumulation of L1 antigen was obtained only when 
the first 14 amino acids of the N-terminal domain of the ATPase beta subunit or the 
Rubisco large subunit were translationally fused to the N-terminal of the L1 protein.
The level of transgene expression in chloroplasts varies depending on the origin 
of the coding sequence. Although the amount of transcript depends on the high 
copy number of the transgenes, it is also closely related to the efficiency of the 
promoter chosen and the regulatory sequences that affect translation. Most of the 
transgenes expressed in chloroplasts utilize the psbA promoter. It has also been 
reported that the 5’UTR sequence of psbA shows higher translation activity com-
pared to many 5’UTR sequences. For this reason, studies connected with improving 
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Viral protein 1 Poliovirus — Nicotiana tabacum Orally (ORV) Biolistic [33]
gp120 and gp41 multiepitope
protein
HIV 16 μg /g fresh weight Nicotiana tabacum Orally (ORV) Biolistic [34]
gp120 and gp41 multiepitope
protein
HIV 16 μg /g fresh weight Nicotiana tabacum Orally (ORV) Biolistic [15]
ESAT-6 and
Mtb72F
Mycobacterium tuberculosis 7.5% for ESAT-6 and 1.2% for 
Mtb72F
Nicotiana tabacum Orally (ORV) Biolistic [35]
mmpI with Lymphotoxin-beta 
(LTB)
Mycobacterium leprae and 
Mycobacterium avium
— Nicotiana benthamiana — Polyethylene 
glycol (PEG)
[36]
C4V3 polypeptide HIV — Nicotiana tabacum Orally (ORV) Biolistic [37]
L1 capsid protein fused with LTB Human papillomavirus 2% Nicotiana tabacum — Biolistic [38]
dengue-3 serotype polyprotein 
(prM/E)





















Staphylococcus aureus 0.7% Chlamydomonas 
reinhardtii
Orally (ORV) Biolistic [41]
VP1 Foot and mouth dis ease virus 
(FMDV)
51% Nicotiana tabacum Inoculated Biolistic [42]
HIV-1 Pr55gag polyprotein HIV 6.75% Nicotiana benthamiana — Biolistic [43]


















Antigens Disease/Pathogen % of Total Soluble Protein or 




E7 and E7CP HPV protein Human papillomavirus 0.1% and 0.5% Nicotiana tabacum — Biolistic [45]
multi-epitope DPT fusion 
protein
Corynebacterium diphtheria, 
Bordetella pertussis, Clostridium 
tetani
0.8% Nicotiana tabacum Orally (ORV) Biolistic [46]
F1-V Yersinia pestis
(Plague)
14.8% Nicotiana tabacum Orally (ORV) Biolistic [47]




L1 capsid protein Human papillomavirus 24% Nicotiana tabacum Intraperitoneal (IP) Biolistic [49]
L1 capsid protein Human papillomavirus 1.5% Nicotiana tabacum — Biolistic [50]
Structural protein E2 Swine
fever virus (CSFV)
1–2% Nicotiana tabacum Subcutaneous and 
intragastric
Biolistic [51]





Severe acute respiratory 
syndrome coronavirus
0.2% Nicotiana tabacum Orally (ORV) Biolistic [53]
Protective antigen
(PA)
Bacillus anthracis (Anthrax) 2.7 and 1.7% Nicotiana tabacum — Biolistic [54]
VP6 Rotavirus 3% Nicotiana tabacum — Biolistic [55]
Table 3. 
Plant-based vaccines developed by chloroplast transformation.
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codon optimization significantly increases translation in chloroplasts [57]. It has 
been indicated that the expression of the gene of the vaccine subunit is increased 50 
times in chloroplasts by codon optimization [33].
In recent years, the production of vaccine antigens in the chloroplasts of edible 
plants like lettuce and ensuring oral vaccination have come to the fore as an impor-
tant development in order to eliminate the economically demanding and extremely 
expensive steps such as fermentation, purification, cold storage, cold chain and 
transportation. Lyophilized plant cells stored at ambient temperature retain their 
efficacy and antigen folding/assembly, thus eliminating the need for cold chain [33]. 
Thus, chloroplast bioreactors have become an important alternative to the production 
of fermentation-based vaccine antigens. Arlen et al. [47] have achieved the production 
of high levels of F1-V antigen, as much as 14.8% of the total soluble protein. In a study 
conducted by aerosol challenge with Y. pestis, 33% of subcutaneously F1-V (with adju-
vant) immunized mice survived, while 88% of orally F1-V immunized mice survived. 
These data presented that oral doses of vaccine antigens produced in chloroplasts may 
be effective in eliciting protective immune responses in vivo. In yet another study, an 
increase in IgG1 and IgA titers was reported with oral boosting of low-cost, cold chain-
free, chloroplast made viral protein 1 (VP1) subunit vaccine [28]. By producing mul-
tiple vaccine antigens in chloroplasts, immunity can be improved against more than 
one infectious disease at the same time. Cholera toxin-B subunit (CTB) fused malarial 
vaccine antigens apical membrane antigen-1 (AMA1) and merozoite surface protein-1 
(MSP1), expressed in lettuce and tobacco chloroplasts inhibited the proliferation of 
malaria in red blood cells by inducing antigen-specific antibodies in mice [40].
Besides terrestrial plant systems, photosynthetic unicellular alga Chlamydomonas 
reinhardtii’s chloroplasts are used for vaccine production against various pathogens. 
Algae vaccines can remain stable at room temperature for more than 1.5 years and 
show faster and more controllable growth characteristics than other members of the 
plant kingdom. D2 fibronectin-binding domain of CTB fused Staphylococcus aureus 
was stably expressed in C. reinhardtii algae and as a result of algae-based inoculation 
of mice, the amount of pathogen decreased and 80% of mice were protected against 
the lethal dose of S. aureus [41]. It was reported in another study that the fusion 
protein was developed against tuberculosis caused by Mycobacterium tuberculosis, 
one of the leading fatal diseases, can be stored in lyophilized leaf for up to 6 months 
at room temperature and preserves its stability and proper folding/assembly [36].
Production of vaccine antigens (HIV gag transgene; Pr55gag) by biolistic-medi-
ated chloroplast transformation resulted in significantly greater protein accumula-
tion than Agrobacterium-mediated nuclear transformation which vaccine antigens 
postranslationally targeted into plastids [43]. In transient expression experiments, 
various cellular organelles (cytosol, apoplast, endoplasmic reticulum, chloroplast 
and mitochondrion) were targeted. It was reported that specific Pr55gag sequences 
were expressed only in chloroplasts. The synthetic gene encoding the HIV C4V3 
recombinant protein known to induce both systemic and mucosal immune 
responses in mammalian systems was expressed in chloroplasts of Nicotiana 
tabacum plants. It has been reported that the obtained plant-derived C4V3 elicits 
systemic and mucosal antibody responses in BALB /c mice by oral immunization 
[37]. Multepitopic protein (Multi-HIV) derived from HIV gp120 and gp41 envelope 
proteins expressed in tobacco chloroplasts also induced immune responses and 
T-helper specific responses by oral immunization in BALB/c mice [34].
2.3 Plant virus based expression system
Plant viruses are generally described as safe for humans and animals. Therefore, 
they are preferred for the production of therapeutic molecules. TMV (tobacco 
Botany - Recent Advances and Applications
14
mosaic virus), PVX (potato virus X), BaMV (bamboo mosaic virus), CPMV 
(cowpea mosaic virus) are highly stable to high temperature, pressure and pH 
conditions and can be purified from host plants in amounts exceeding hundreds of 
mg/kg plant biomass [58]. Virus-like particles (VLPs) are multi-subunit molecules 
consist of self-assembly protein structures that are the same or highly similar to the 
general structure of authentic virus. Due to the fact that VLPs do not contain viral 
nucleic acids, therefore conversion to infectious viruses is not possible which is an 
important risk factor for attenuated vaccines. In recent years, the use of both VLPs 
and plant viruses for vaccine production has increased rapidly (Table 4). There are 
various recombinant vaccine production strategies that stand out in which different 
vaccine antigens can be produced by using plant viral structures. Launch vector-
based on virus for plant transient expression system, plant virus-based vector 
systems by the incorporation of 2A peptide, plant virus conjugated with purified 
antigen from bacterial expression system are some of the systems by which recom-
binant vaccine antigens can be produced.
Multiple doses of multivalent vaccine can be administered in the immuniza-
tion of mice without any adverse effects. In addition, multivalent subunit vaccines 
can be developed against various diseases using an efficient TMV-based delivery 
platform. A multivalent subunit vaccine consisting of the combination of OmpA, 
DnaK chaperone and Tul4 protective antigens of the Francisella tularensis patho-
gen bacterium has been reported to be safe. F. tularensis proteins were chemically 
conjugated to the TMV surface and the developed subunit vaccine strongly induced 
humoral immune response [60]. Chen et al. [59] produced a candidate vaccine 
(BJ2A CVP) in Chenopodium quinoa and N. benthamiana against Japanese encepha-
litis virus (JEV) using a bamboo mosaic virus-based chimeric virus particle (CVP) 
strategy. Chenopodium quinoa plant is preferred to reduce the side effects of nicotine 
and other alkaloids found in tobacco species in the purification of BJ2A CVP.
The genomes of both RNA and DNA viruses can be modified for recombinant 
protein production. Geminiviral replicon systems are one of the plant-viral based 
expression systems used to increase the expression of vaccine antigens in plants. 
In geminiviral derived vectors with a single stranded DNA genome, the viral genes 
encoding the coat and movement proteins are deleted and the expression cassette 
for protein of interest is inserted. In these strategies, it has been reported that the 
viral vector has transient expression only 4 days after it was transferred to Nicotiana 
benthamiana plant leaves by Agrobacterium infiltration and maintained this expres-
sion level up to 7 days [70]. On the other hand, by using plants with low secondary 
metabolite content such as lettuce in geminiviral replicon systems based on bean 
yellow dwarf virus, virus-like particles could be produced at high expression levels. 
Thus, vaccine candidates such as Norwalk virus capsid protein-VLP (NVCP-VLP) 
can be purified from lettuce plants without losing their functional activity. Plant 
virus-based expression methods along with Agrobacterium-mediated agroinfiltra-
tion are often preferred for increasing low expressions of vaccine antigens in plants 
and improving the feasibility of plant-based vaccines. The expression of recombi-
nant proteins were carried out in Nicotiana benthamiana plant by using the Launch 
vector-based plant transient expression system with agroinfiltration, and it was 
reported that vaccine candidates caused up to 100% protection against diseases that 
could be used for bioterrorism such as anthrax after purification [63]. In another 
study, it has been reported that Consensus domain III of dengue virus E glycopro-
tein (cEDIII) shows high expression with plant virus-based expression (5.2 mg/g 
dry weight of leaf tissues) against Dengue virus [61]. Launch vector technologies, 
which are used in the production of VLP-based recombinant vaccines especially 
against infectious diseases, are also used in the production of protective vaccines 
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sporogonic development of the sexual stage Plasmodium falciparum parasites 
ingested by female Anopheles mosquitoes [64]. Thus, the spread of parasites in 
endemic populations by transmission from human to mosquito is prevented [41]. 
Another plant virus-based expression approach is the fusion of the vaccine antigen 
to the virus-like carrier particle, either genetically or by chemical cross-linking [67]. 
It has been reported that the potato X virus-based recombinant viral vector pro-
vides a high level of expression of the hybrid protein consisting of influenza virus 
M2 protein (M2e) fused to hepatitis B core antigen (HBc) in Nicotiana benthamiana 
plants. This vector was transferred to plant leaves by agroinfiltration and the hybrid 
protein was synthesized to 1–2% of the total soluble protein.
2.4 Transient expression
In addition to stable transgene expression (nuclear or plastid transformation), 
transient expression is often preferred for the expression of genes encoding vaccine 
proteins in plant tissues. Since transient expression does not contain chromosomal 
integration, it is not affected by position effect. In addition, the expression of 
extrachromosomal transgenes can be detected 3 hours after transfer and can last for 
about 10 days [14]. The major advantage of transient expression is production of 
vaccine antigen rapidly at low cost and high yield. In addition, the easy applicability 
of the system and its ability to allow the production of complex proteins composed 
of subunits encourages its use against the novel viral diseases that emerge suddenly. 
Plant-based vaccines developed by transient expression are given in Table 5.
Margolin [73] achieved Agrobacterium-mediated transient expression of soluble 
HIV Env gb140 antigens in Nicotiana benthamiana plant. It has been reported that 
rabbits immunized intramuscularly with lectin affinity purified antigens developed 
binding antibodies and neutralizing antibodies at high titers. The production of 
nucleo capsid (N) and membrane protein (M), two important antigens of SARS-
CoV, was achieved in Nicotiana benthamiana plant with transient expression 
created by using both virus-based vector and agroinfiltration. In addition, tobacco 
leaves infiltrated with Agrobacterium tumafaciens C58 and GV3101 strains harbor-
ing the pBI-Mvector containing the M protein, SARS-CoV M protein production 
was successfully achieved without using any post-transcriptional gene silencing 
 suppressors [78].
It is imperative to produce vaccines at rates which offset mutation frequency 
of viral infections such as influenza, for which a new and unique epidemic strain 
appears within a few years. In recent years, recombinant vaccines become promi-
nent as one of the most important options to solve this problem. New recombinant 
strategies provided by plant biotechnology and the production of plant-based 
vaccines are becoming widespread in the struggle with pandemic and epidemic 
diseases such as Influenza A H1N1, Influenza H5N1, plague, Ebola, Zika, SARS-
CoV and SARS-Cov-2 [78–81]. Plant-based vaccines developed for pandemic and 
epidemic diseases are given in Table 6.
Especially the commercial scale production of these vaccines and their exami-
nation at Phase I, Phase II and Phase III levels beyond the functional evaluations 
in animal models indicates that in the future, plant-derived vaccines will be an 
important part of the struggle against pandemic and epidemic diseases. Plant-
based vaccines produced in commercial scale and candidate vaccines are given in 
Table 7 by companies. For instance, COVID-19 (severe acute respiratory syndrome 
coronavirus 2/SARS-CoV-2), which has become a major threat to global health, has 
also significantly impacted the world economy and social mobility. So far, with its 
high contagiousness, rapid spreading nature and high mortality rate, more than 2.5 
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FW: Fresh Weight, Tsb: Total Soluble Protein, NA: Not Available, CaMV: Cauliflower Mosaic Virus.
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P: Pandemic, E: Epidemic, FW: Fresh Weight, Tsb: Total Soluble Protein, NA: Not Available, DW: Dry Weight. NT: Nicotiana tabacum, LE: Lycopersicon esculentum.
Table 6. 
Plant-based vaccines developed for pandemic and epidemic diseases.
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been infected with COVID-19 worldwide [97]. In order to control the pandemic, 
the whole world work hard to develop new strategies to be applied in the field of 
health, to deliver vital medical supplies to those in need, to develop and apply safe 
and effective vaccines. Especially, the development of vaccines and drugs for this 
new pathogenic Coronavirus, which emerged suddenly and mutated at certain 
times, became an inevitable target. Until now, the number of vaccines in preclini-
cal development are 182 and the number of vaccines in clinical development is 74, 
worldwide [8]. Plant-based vaccines have also proven that they can play an active 
role in fighting against COVID-19 with their promising results in preclinical and 
clinical stages. Along with the initiative of commercial companies using plant bio-
technology, transient expression of the SARS-CoV-2 antigen in plants was achieved, 
and a plant-based COVID-19 vaccine candidate was produced with a high-scale 
production technology [81]. The COVID-19 vaccine developed by Medicago com-
pany using a plant-based platform started Phase II clinical trials. In this approach, 
virus-like particles (SARS-CoV-2 spike protein self-assambles into VLPs) could 
be produced by transient expression in Nicotiana benthamiana plants within just 
20 days after the acquisition of SARS-CoV-2 [81]. For Phase I, vaccine administra-
tion in healthy adults was performed as two intramuscular doses and at 3 different 
dose levels (S protein content 3.75, 7.5 or 15 μg), either alone or with adjuvant (AS03 
or CpG1018). After the second dose administration, the adjuvanted CoVLP was 




spike protein fused 
lichenase protein / 
Nicotiana benthamiana
IBIO-400
Prophylaxis of Classical swine fever (CSF)
CSFV E2 glycoprotein / Nicotiana benthamiana
Medicago Inc. [92]
MT-7529
Prophylaxis of H7N9 
influenza / Phase 2 / 
Nicotiana benthamiana
MT-2355
Prophylaxis of pertussis, 
diphtheria, tetanus, poliomyelitis 
and prophylaxis of Hib infection 
in infants /
Phase 3 / Nicotiana benthamiana
MT-2271
Prophylaxis of seasonal 
influenza / Nicotiana 
benthamiana
MT-5625
Prophylaxis of rotavirus 
gastroenteritis / Phase 1 / 
Nicotiana benthamiana
MT-2766
Prophylaxis of SARS-CoV-2/ 
Phase 2 / Nicotiana benthamiana
MT-8972
Prophylaxis of H5N1 
influenza / Phase 2 / 
Nicotiana benthamiana
Icon Genetics [93, 
94]
ZMapp
Prophylaxis of Ebola virus / 
Nicotiana benthamiana
Norovirus Vaccine
Prophylaxis of Norovirus / Phase I / Nicotiana benthamiana
SoyMeds, Inc. [95]
soy-mSEB
Prophylaxis of Staphylococcal Enterotoxin B / Glycine max
Fraunhofer CMB [96]
Prophylaxis of H1N1 
influenza
Prophylaxis of H1N1 influenza Prophylaxis of Malaria
Table 7. 
Plant-based vaccines producing companies and commercial products.
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BAT’s US Bio-tech arm, Kentucky BioProcessing (KBP), announced that the 
COVID-19 vaccine candidate will be evaluated in the Phase I trial after the Food and 
Drug Administration (FDA) accepts the Investigational New Drug application. This 
candidate vaccine was developed using plant-based technology and it was stated 
that the active ingredient of the vaccine could be rapidly produced in a short period 
of 6 weeks according to conventional methods. In still another initiative, iBio, Inc. 
company announced that it was working on the subunit IBIO-201 candidate vaccine 
against SARS-CoV 2 immediately after the pandemic was declared. The candidate 
vaccine was produced by Agrobacterium-mediated infiltration in leaves of Nicotiana 
benthamiana plants and the target protein was purified and formulated for the 
final product. The candidate vaccine has been reported to induce the production of 
anti-spike neutralizing antibodies in immunized mice. Due to the new mutations of 
SARS-CoV-2, it has become important to produce subunits or virus-like particles as 
vaccine candidates at low cost-per-dose and higher production scale.
2.5 Evaluation of plant-based vaccines side effect
Vital part of vaccine research is the risk assessment through randomized, 
double-blind placebo-controlled multicentre trials. Vaccine side effects can be 
evaluated under two categories as common side effects (high fever, vomiting, 
dizziness, anxiety and nausea) and rare side effects (risk of hospitalization, death 
or long-term morbidity). Same evaluation processes is required for plant-based 
vaccines as all traditional and recombinant vaccines. In literature, there are various 
studies in emphasis to safety and side effects of plant-based vaccines.
Plant-based vaccines can be evaluated in two different ways: cases in which 
the plant content is directly applied in pure form and the cases where the vaccine 
content is isolated and mixed with adjuvant. Phase studies were initiated for many 
candidate vaccines, where antigen or VLP was produced and then mixed with adju-
vant before injection. In reported Phase I vaccine case against influenza A presented 
common side effects on volunteers as high fever, vomiting, dizziness, anxiety and 
nausea [96]. Similarly, in another case local effects occurred in the vaccination area 
and 93% of side effects were mild effects [98]. McCormick et al., stated in their 
studies that volunteers showed symptoms that were described as severe at a very 
low rate, but recovered within 1–2 days without the need for medical intervention, 
and the vaccine candidate was quite safe [99]. Moreover, Pillet et al. tested the vac-
cines with 300 healthy adults and 450 volunteers over the age of 50 in their phase III 
study on two different age groups. As a result, a higher rate of fatigue was observed 
in volunteers over 50 years old [100]. Ward et al. reported that the most common 
side effect was pain at the injection site in their studies on 22,854 volunteers and 
mortality rate was slightly higher for inactivated.
vaccine comparing to virus like particles [101]. Chichester et al., (2018) reported 
that 94% of the volunteers developed at least one of the side effects of high fever, 
vomiting, dizziness, anxiety and nausea [102]. In all of these studies with both oral 
and injectable vaccines, the observed effects were evaluated as mild to moderate. In 
this way, plant-based production has been defined as an effective and safe vaccine 
production tool [103]. Production of the adjuvants to be used to stimulate mucosal 
and peripheral immunity in the plant or the selection of plant which produce 
appropriate secondary metabolites that can act as mucosal adjuvants contributes 
to the decrease in the incidence of side effects. The number of studies in which 
plant-based vaccine candidates have passed to phase studies were much less than 
classical vaccine studies. When these studies are evaluated, there is no significantly 
increased side effect risk report concerning plant-based vaccines against any other 
vaccines production options [104].
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2.6 Legal regulations involving plant-made pharmaceuticals
Regulatory processes of the vaccine development, approval, authorization, 
licensing, distribution, and marketing are as challenging as the production. There 
are both national and centralized regulatory agencies. These agencies emphasize 
on scientific evaluation of data, quality of the product, safety for human use, 
verification of reported efficacy and authenticity of product labels. In USA, central-
ized regulatory agency is Food and Drug Administration known as FDA. As plant 
based-vaccines are considered in biological materials apart from chemical entities, 
plant-made pharmaceutics are regulated under Biologics License Application (BLA) 
[105]. The European Union (EU) members have both their own national regulation 
and the centralized regulation under European Medicines Agency (EMA) which 
acts as the counterpart of FDA in Europe. The Committee on Herbal Medicinal 
Products (HMPC) is the EMA’s committee responsible for compiling and assessing 
scientific data on herbal substances, preparations and combinations, to support the 
harmonization of the European market [106]. However, considering the nature of 
plant based vaccines, they are under authorization of The Committee for Medical 
Products for Human Use (CHMP) which plays a vital role in the authorization of 
medicines in the European Union (EU).
Strictness of the regulation is mostly based on the production method and the 
host plant. Non-food plants as Nicotiana species and the controlled indoor produc-
tion methods as plant tissue cultures or climate rooms are not regulated as strictly 
as in field production of GM food plants. However, there are opinion differences 
between EU and USA regarding the plant-made PMPs. In USA, regulation is at 
product level. Field use of GM plants and plants used in vaccine development are 
under secondary regulation of United States Department of Agriculture (USDA). 
In May, 2020 USDA Animal and Plant Health Inspection Service (APHIS) released 
revision on 7 Code of Federal Regulation (CFR) Part 340 regulations (85 Fed. Reg. 
29790) which regulates the importation, interstate movement, and environmental 
release of genetically engineered organisms that are or may be plant pests [107]. 
Therefore, scrutiny on biotechnological production is further reduced in favor of 
researchers and companies. PMPs are currently under regulation of Title 21 (Food 
and Drugs) US CFR along with other traditionally produced counterparts. In EU 
regulation is on both production and final product level. All GM plant derived phar-
maceuticals including plant based vaccines are under the same regulation of other 
biotechnology derived drugs which is indicated in European Commission Directive 
2001/83/EC (on the Community code relating to medicinal products for human 
use) [108] and Regulation No 726/2004 (for the authorization and supervision of 
medicinal products for human and veterinary use) [109]. Also, if the host plant is 
a human food or animal feed source, cultivation and release of GM plant is under 
regulation of EC Directive 2001/18/EC (on the deliberate release into the environ-
ment of genetically modified organisms) [110] and 1829/2003/EC (on genetically 
modified food and feed).
Regulatory approval of a PMPs and other biotechnologically derived products 
may take up to a year depending on the legal response limits of the regulation 
agencies. However, Covid-19 pandemic triggered a realization on EU and UK for 
national and global needs. Therefore, product review, conditional approval and 
deployment timelines are significantly reduced for PMPs [111].
In conclusion, infectious diseases threatened humanity countless times through-
out history. In particular, as pandemic and epidemic diseases killed millions of 
people, it increases in importance to develop safe and cost-effective vaccines and 
their storage and rapid distribution. Apart from many diseases such as diphtheria, 
cholera, typhoid, tuberculosis, which are controlled by vaccine campaigns in 
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developed countries, new vaccine production systems using recombinant DNA 
technologies are needed for emerging diseases such as COVID-19, MERS-CoV, avian 
influenza, Ebola, Zika and possible future infections. Plant-based vaccine produc-
tion for humans and animals stands out as an important alternative that can be used 
to overcome the disadvantages of existing conventional vaccines. Within the scope 
of plant biotechnology, it became possible to produce cost-effective, immunogenic 
and safe vaccines thanks to the development of gene transfer strategies to plants 
and improvements in amount, isolation and purification and addition of adjuvant 
for production of recombinant vaccine antigens in plants. It is an undeniable fact 
that the possibilities that recombinant vaccines can offer us will increase with new 
standards and legal regulations to be introduced for the development, approval, 
authorization, licensing, distribution and marketing of such vaccines. In scope 
of future preventive healthcare, it is hard to assume monopoly of one particular 
vaccine technology. There will always be some ups and downs in any vaccine 
production methods. However, plant based vaccines represent considerable strong 
suits and offer swift and viable solutions over traditional and other recombinant 
vaccines.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
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